Myriad Genetics, Inc. (MYGN)
3.16
-0.02
(-0.63%)
USD |
NASDAQ |
Aug 28, 16:00
3.145
-0.02
(-0.47%)
After-Hours: 20:00
Myriad Genetics Cash from Operations (Quarterly) : -8.30M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.30M |
| March 31, 2026 | -15.70M |
| December 31, 2025 | 10.60M |
| September 30, 2025 | 21.10M |
| June 30, 2025 | -13.60M |
| March 31, 2025 | -16.30M |
| December 31, 2024 | 6.60M |
| September 30, 2024 | 0.70M |
| June 30, 2024 | 2.60M |
| March 31, 2024 | -18.60M |
| December 31, 2023 | -54.70M |
| September 30, 2023 | -22.10M |
| June 30, 2023 | -0.90M |
| March 31, 2023 | -33.20M |
| December 31, 2022 | -7.70M |
| September 30, 2022 | -2.50M |
| June 30, 2022 | -50.30M |
| March 31, 2022 | -46.50M |
| December 31, 2021 | -9.90M |
| September 30, 2021 | -39.30M |
| June 30, 2021 | -4.40M |
| March 31, 2021 | 70.60M |
| June 30, 2020 | 29.00M |
| March 31, 2020 | 16.80M |
| December 31, 2019 | -1.90M |
| Date | Value |
|---|---|
| September 30, 2019 | 15.80M |
| June 30, 2019 | 31.50M |
| March 31, 2019 | 6.60M |
| December 31, 2018 | 37.80M |
| September 30, 2018 | 7.80M |
| June 30, 2018 | 47.90M |
| March 31, 2018 | 11.50M |
| December 31, 2017 | 33.00M |
| September 30, 2017 | 23.50M |
| June 30, 2017 | 36.60M |
| March 31, 2017 | 41.10M |
| December 31, 2016 | 31.40M |
| September 30, 2016 | -2.90M |
| June 30, 2016 | 38.50M |
| March 31, 2016 | 62.00M |
| December 31, 2015 | 40.90M |
| September 30, 2015 | 24.90M |
| June 30, 2015 | 51.04M |
| March 31, 2015 | 29.88M |
| December 31, 2014 | 52.60M |
| September 30, 2014 | 6.981M |
| June 30, 2014 | 40.93M |
| March 31, 2014 | 11.25M |
| December 31, 2013 | 47.55M |
| September 30, 2013 | 90.48M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Natera, Inc. | 54.79M |
| Sera Prognostics, Inc. | -6.311M |
| BioRestorative Therapies, Inc. | -3.808M |
| CareDx, Inc. | 30.60M |
| Exagen, Inc. | 3.988M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.20M |
| Cash from Financing (Quarterly) | 2.20M |
| Free Cash Flow | -14.20M |
| Free Cash Flow Per Share (Quarterly) | -0.1213 |
| Free Cash Flow to Equity (Quarterly) | -10.50M |
| Free Cash Flow to Firm (Quarterly) | -7.342M |
| Free Cash Flow Yield | -4.79% |